Singapore Data Center Runs on 4 Million Human Neurons

A Living Data Center Debuts in Singapore

A new kind of computing facility has switched on inside the National University of Singapore's Life Sciences Institute, and it runs on biology rather than pure silicon. The prototype, built by Australian biotech firm Cortical Labs in partnership with NUS Medicine and Singapore-based data-center operator DayOne, is powered by an estimated 4 million living human neurons grown in the lab 1. Unlike conventional server racks that simply need power and cooling, this system requires actual care: staff must feed the neural cultures every three days to keep them alive and functioning 1.

How Neurons Become Processors

The underlying concept, sometimes described as "biological computing" or "wetware," uses lab-grown neurons arranged on electrode arrays that can both stimulate and read electrical activity from living brain cells. Cortical Labs has previously demonstrated that clusters of neurons can be trained to perform simple tasks, such as playing rudimentary video games, by rewarding certain firing patterns. Housing this technology inside an operational data-center environment in Singapore marks an attempt to move the idea from laboratory curiosity toward a working prototype with real infrastructure partners, including a commercial data-center firm in DayOne 1. The pitch behind such systems is that biological neurons may eventually offer energy efficiency or learning capabilities that differ from traditional chips, though the Singapore facility remains an early-stage, small-scale proof of concept rather than a commercial-grade replacement for digital servers 1.

Part of a Broader Biotech Momentum

The neuron-powered data center lands amid a broader wave of activity across the biotechnology sector, even if the underlying stories are largely unrelated in substance. Financial markets have shown renewed enthusiasm for biotech stocks, with the sector reportedly hitting a post-pandemic high following a positive Moderna trial result 57, while analysts at JPMorgan have pointed to a broader biotech investment rebound as a tailwind for companies like Charles River Laboratories 2. Fund managers have also highlighted strong recent returns from biotech-focused portfolios, with one fund citing performance well above the sector's benchmark index over five years 6. Separately, stock-market news trackers continue to monitor FDA approvals, clinical trials, and biotech headlines heading into 2026 3.

The sector's reach extends into consumer health as well, with fitness-tracker maker Whoop opening its blood-testing service, including Grail's Galleri multi-cancer early-detection test, to users without requiring a membership 8. On a less flattering note, biotech credentials also surfaced in political controversy, as a report alleged that the mother of an Ohio gubernatorial candidate manipulated data at a biotech firm central to his business background 4.

Why It Matters

Taken together, the coverage illustrates a biotech landscape moving in several directions at once: speculative frontier science like neuron-based computing in Singapore, a resurgent investment climate on Wall Street, expanding consumer access to advanced diagnostics, and continued scrutiny of biotech figures in public life. The Singapore project, while still experimental, signals growing interest in blending biological systems with computing infrastructure, a development likely to draw both scientific curiosity and ethical questions as it advances beyond prototype stage 1.